WallStSmart

Perspective Therapeutics Inc. (CATX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 5884043% more annual revenue ($36.36B vs $618,000). MDT leads profitability with a 13.2% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 62/100 (C+).

CATX

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -0.43

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CATX.

MDTUndervalued (+11.4%)

Margin of Safety

+11.4%

Fair Value

$91.83

Current Price

$81.67

$10.16 discount

UndervaluedFair: $91.83Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CATX2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$103.20B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

CATX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$335.30M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

MDT2 concerns · Avg: 3.5/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CATX

The strongest argument for CATX centers on Price/Book, Debt/Equity.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : CATX

The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CATX carries more volatility with a beta of 1.73 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (62/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Perspective Therapeutics Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?